Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
Open accessThe DOI matches its Crossref record; 24 of the 26 references it cites were found in a registry or an index; 6 of the 44 sources its claims cite were checked for support.
Abstract
As the first radiopharmaceutical for Peptide Receptor Radionuclide Therapy (PRRT), Lutathera® was approved by the EMA in 2017 and the FDA in 2018 for the treatment of somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors.
Overview
CoChat Summary
## TL;DR
Lutathera® ([177Lu]Lu-DOTA-TATE) is presented as the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy (PRRT) for adults with SSTR-positive gastroenteropancreatic neuroendocrine tumors. The paper summarizes its mechanism, indication, dosing, manufacturing, and the clinical trial results that supported approval.
## Key findings
- Lutathera® was approved by the EMA in 2017 and the FDA in 2018; the paper also notes Canadian approval in 2019.
- Its active ingredient is [177Lu]Lu-DOTA-TATE, which combines lutetium-177 with the somatostatin analogue DOTA-TATE to target SSTR-expressing tumor cells and cause DNA single- and double-strand breaks.
- The recommended treatment schedule is four infusions of 7.4 GBq every 8 weeks; intervals may be extended to 16 weeks if dose-modifying toxicity occurs.
- In the NETTER-1 phase III trial (229 patients), progression-free survival favored [177Lu]Lu-DOTA-TATE plus octreotide LAR over high-dose octreotide LAR: 65% vs 11% of patients were progression-free at 20 months (p < 0.0001), median PFS was not reached vs 8.5 months, and objective response rate was 18% vs 3% (p < 0.001).
## Methods
- Narrative review/overview of Lutathera® covering chemical properties, clinical indication, application, pharmacology/pharmacokinetics, manufacturing, and regulatory status.
- Draws on published clinical studies and product monographs, including the Erasmus phase I/II study (1,214 patients) and the NETTER-1 phase III trial (229 patients).
- Summarizes reported trial endpoints and pharmacokinetic/dosimetry data from the cited studies rather than presenting new original analyses.
## Limitations
- The paper does not report any new original experimental or clinical data; it synthesizes prior literature and regulatory documents.
- The text makes evident that some sections are only brief summaries and refer readers to product monographs or cited studies for details; this limits methodological depth and reproducibility of the review’s own synthesis.
- Not stated in the paper.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
5 Valid · 0 Not valid · 33 Not checked · 1 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The positive results of the multicenter phase-III clinical trial [16], NETTER-1, comparing the treatment with [177Lu]Lu-DOTA-TATE to the treatment with high doses of octreotide LAR, paved the way for its approval by national and international medicines agencies in America and Europe.”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 4. Conclusions
What the sources say
- Partly supportedcites [16] Strosberg, 2017, NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Another therapeutic effect is the radiation-induced bystander effect: Cells that have not been directly exposed to ionizing radiation, but are in the neighborhood of such cells, behave as if they have been directly hit [31].”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 3. Medicinal and Pharmaceutical Overview > 3.3. Pharmacology and Pharmacokinetics In a study by Reubi et al. [29], the SSTR subtype affinity profile of a number of somatostatin analogues was investigated, showing, e.g., that DOTA-TATE exhibits high affinity for human SSTR2 (IC50 of 1.5 ± 0.4 nM) with much less binding affinity for all other human SSTRs. Complexing this peptide with yttrium resulted in a comparable binding affinity profile and complexing with gallium in an even higher affinity for SSTR2 (IC50 of 0.2 ± 0.04 nM). [177Lu]Lu-DOTA-TATE shows high binding affinity for SSTR2 as well, and therefore binds to malignant cells with an upregulation of SSTR2 [8]. Upon binding to the receptor, the radiolabeled peptide becomes internalized into the cell and the β particle emission of 177Lu induces DNA single- and double-strand breaks, in case of double-strand breaks leading to cell death of the tumor and its SSTR-positive lesions [8]. Figure 2 gives a simplified overview on the mechanism of action of [177Lu]Lu-DOTA-TATE. Due to the range of the β particles in comparison to the diameter of a cell, the emitted β particles traverse several cells (10–1000) [30]. This effect has been termed “cross-fire effect” and is responsible for the possible destruction of multiple cells in the vicinity of the tracer-accumulating cell [31]. Using β particle emitters, the cross-fire effect is critical for the improvement of tumor dose homogeneity and for ensuring a sufficient dose for each cell [32]. Another therapeutic effect is the radiation-induced bystander effect: Cells that have not been directly exposed to ionizing radiation, but are in the neighborhood of such cells, behave as if they have been directly hit [31]. Owing to the nanomolar concentration (10 µg/mL; 6.3 × 10−3 nM) of the peptide in the sterile injection solution [8], no clinically relevant pharmacodynamic effects are expected. The pharmacokinetic properties of Lutathera® are described in the product monographs [8,27]. [177Lu]Lu-DOTA-TATE is immediately and completely bioavailable through i. v. injection and clears rapidly from blood. The effective half-life in blood in a study with 31 patients was determined to be 0.31 ± 0.13 h [33]. The effective blood elimination half-life is 3.5 ± 1.4 h [26]. Studies using non-radioactive [175Lu]Lu-DOTA-TATE showed that protein binding to human plasma is ca. 50% and that transchelation of lutetium to serum proteins is not occurring. Four hours after administration, [177Lu]Lu-DOTA-TATE shows uptake in kidneys, tumoral lesions, liver, and spleen, and in some patients, additionally in the pituitary gland and thyroid. Kidney uptake can be decreased by co-administration of amino acids (see above), which reduces the re-absorption of the radiopharmaceutical through the proximal tubules [34]. This is mandatory because the compound is primarily eliminated through the renal system. Data from the Erasmus phase-I/-II and NETTER-1 phase-III trials indicate that ca. 60% of the radiopharmaceutical is eliminated in the urine within 24 h post injection (p. i.) and ca. 65% within 48 h p. i. Metabolism of [177Lu]Lu-DOTA-TATE is negligible, as shown by radio-HPLC analysis of urine samples collected 48 h p. i. Radiation dosimetry of [177Lu]Lu-DOTA-TATE has been evaluated in 20 patients in clinical studies [15,27]. The critical organ is the bone marrow. However, with the recommended cumulative dose of 29.6 GBq (4 × 7.4 GBq), neither correlation of hematological toxicity with total administered radioactivity nor with bone marrow absorbed dose has been observed. The kidney is not a critical organ when co-administration of appropriate amino acids is conducted. The median radiation dose to the kidneys can be reduced by 47% (34% to 59%) with co-administration of amino acids [26]. Table 1 summarizes estimated radiation absorbed doses for Lutathera® in the NETTER-1 trial for main organs [26,27].
What the sources say
- Supportedcites [31] Haberkorn, 2017, The Future of Radioligand Therapy: α, β, or Both?, J. Nucl. Med. source
The discussion of the radiation-induced bystander effect (p. 1) explicitly defines it as neighboring cells that were not directly exposed to ionizing radiation behaving as though they were exposed. The Figure 1 caption (p. 2) likewise describes effects on neighboring, unexposed cells. (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim could be matched to a paper, so there is nothing to check it against.
In the paper
“The clinical indication of Lutathera® is the treatment of unresectable or metastatic, progressive, well-differentiated (G1 and G2 grade) SSTR-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults [15,27].”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 3. Medicinal and Pharmaceutical Overview > 3.1. Clinical Indication
What the sources say
- Not matchedcites [15] (2019, April 23). Lutathera® Summary of Product Characteristics. Available online: https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf.
We searched by its title and found no matching paper.
- Not matchedcites [27] (2019, April 23). Product Monograph for LUTATHERATM for Canada. Available online: https://pdf.hres.ca/dpd_pm/00049099.pdf.
We searched by its title and found no matching paper.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“It could also be demonstrated that treatment with [177Lu]Lu-DOTA-TATE was safe and well tolerated [8].”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > 1. Introduction
What the sources say
- Not matchedcites [8] (2019, April 18). Product Monograph LUTATHERA®. Available online: https://www.samnordic.se/wp-content/uploads/2018/05/LUTATHERA-MONOGRAPH-120218.pdf.
We searched by its title and found no matching paper.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“Using the concept of PRRT, Lutathera® combines the radionuclide 177Lu with the somatostatin analogue DOTA-TATE, thus delivering ionizing radiation specifically to tumor cells expressing somatostatin receptors.”
- Also stated in: § 4. Conclusions · plain
“Combining the radionuclide 177Lu with the somatostatin analogue DOTA-TATE, [177Lu]Lu-DOTA-TATE delivers ionizing radiation specifically and selectively to tumor cells expressing SSTRs.”
§ Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy > Abstract
What the sources say
- Not matchedcites [8] (2019, April 18). Product Monograph LUTATHERA®. Available online: https://www.samnordic.se/wp-content/uploads/2018/05/LUTATHERA-MONOGRAPH-120218.pdf.
We searched by its title and found no matching paper.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 4. Conclusions · plain
12 more claims
Create a free account to see all 39 claims and to verify the 4 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 3
Citations
Cites
Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone
Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., & Guillemin, R. (1973) · Science · doi:10.1126/science.179.4068.77 · Cited by 3,532 · cited 1×
“The development of these radiolabeled somatostatin ligands was a very long scientific journey that started with the first description of somatostatin more than 45 years ago [10].”
BackgroundPhase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Reubi, J. C., Schär, J.-C., Waser, B., Wenger, S., Heppeler, A., Schmitt, J. S., & Mäcke, H. R. (2000) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050034 · Cited by 1,127
LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN
Krenning, E. P., Breeman, W. A. P., Kooij, P. P. M., Lameris, J. S., Bakker, W. H., Koper, J. W., Ausema, L., Reubi, J. C., & Lamberts, S. W. J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91258-0 · Cited by 625 · cited 1×
“The first radiolabeled SST analog used for imaging was [123I, Tyr3]octreotide in 1989 [12], while early therapeutic studies used [111In]In-DTPA-octreotide in the mid to late 1990s, since other chelated somatostatin ligands were not available [11].”
MethodSomatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
Kwekkeboom, D. J., Kam, B. L., van Essen, M., Teunissen, J. J. M., van Eijck, C. H. J., Valkema, R., de Jong, M., de Herder, W. W., & Krenning, E. P. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0078 · Cited by 466 · cited 1×
“The first radiolabeled SST analog used for imaging was [123I, Tyr3]octreotide in 1989 [12], while early therapeutic studies used [111In]In-DTPA-octreotide in the mid to late 1990s, since other chelated somatostatin ligands were not available [11].”
MethodAntibody-targeted radiation cancer therapy
Milenic, D. E., Brady, E. D., & Brechbiel, M. W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1413 · Cited by 380
Consensus nomenclature rules for radiopharmaceutical chemistry — Setting the record straight
Coenen, H. H., Gee, A. D., Adam, M., Antoni, G., Cutler, C. S., Fujibayashi, Y., Jeong, J. M., Mach, R. H., Mindt, T. L., Pike, V. W., et al. (2017) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2017.09.004 · Cited by 226 · cited 1×
“In January 2018 (26 January 2018), Lutathera® ([177Lu]Lu-DOTA-TATE (for rules on nomenclature, see [1,2])) was approved by the FDA [3] for the treatment of somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumors.”
BackgroundElschot, M., Vermolen, B. J., Lam, M. G. E. H., de Keizer, B., van den Bosch, M. A. A. J., & de Jong, H. W. A. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055742 · Cited by 209
Targeted α-therapy–past, present, future?
Brechbiel, M. W. (2007) · Dalton Transactions · doi:10.1039/b704726f · Cited by 151
Crystal structure and solution dynamics of the lutetium(III) chelate of DOTA
Aime, S., Barge, A., Botta, M., Fasano, M., Danilo Ayala, J., & Bombieri, G. (1996) · Inorganica Chimica Acta · doi:10.1016/0020-1693(96)05130-4 · Cited by 148
Research works printed but not linked: 3
- Erion, 1999, High radiotherapeutic efficacy of [Lu-177]-DOTA-Y3-octreotate in a rat tumor model [abstract], J. Nucl. Med., 40, 223
- Nagy, 2004, Radionuclide Therapy, Handbook of Nuclear Chemistry, Volume 4, 315
- Rolleman, 1996, Inhibition of Renal Uptake of Indium-111-DTPAOctreotide, J. Nucl. Med., 37, 1388
Cited by
Items 301–400 of 426
Spahn, M. A., Anbuhl, S. M., Luyten, K., Loy, T. V., Pronker, M. F., Cawthorne, C., Deroose, C. M., Schols, D., Heukers, R., Bormans, G. M., et al. (2025) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.5c00024 · Cited by 2
Hofmann, M., Kunte, S. C., Unterrainer, M., Delker, A., Holzgreve, A., Toms, J., Gildehaus, F. J., Auernhammer, C. J., Spitzweg, C., Zacherl, M. J., et al. (2025) · Cancers · doi:10.3390/cancers17091423 · Cited by 2
“Subsequently, based on these findings, the first radiopharmaceutical for PRRT Lutathera ® was approved by the European Medicines Agency (EMA) in 2017 and by the U.S. Food and Drug Administration (FDA) in 2018 [7].”
Advances in Chemical Conjugation of Natural Cysteine: Techniques and Applications
Li, J., Zhang, Z., Loh, T., & Xu, K. (2025) · Synlett · doi:10.1055/a-2594-9636 · Cited by 2
From Seeing to Healing: The Clinical Potential of Radiotracers in Pediatric Neuro-Oncology
Bogdanović, B., & Montemagno, C. (2025) · Cancers · doi:10.3390/cancers17121905 · Cited by 3
Moon, S., & Lee, J. B. (2025) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2025.08.042 · Cited by 2
Fricke, U., Hein, L., & Schwabe, U. (2020) · Springer eBooks · doi:10.1007/978-3-662-62168-4_2 · Cited by 6
Mitrofanov, Y. A., Bubenshchikov, V. B., Belousov, A. V., et al. (2023) · High Energy Chemistry · doi:10.1134/s0018143923010095 · Cited by 2
Tuning the lipophilic nature of pyclen-based 90Y3+ radiopharmaceuticals for β-radiotherapy
Fur, M. L., Fougère, O., Lepareur, N., Rousseaux, O., Tripier, R., & Beyler, M. (2021) · Metallomics · doi:10.1093/mtomcs/mfab070 · Cited by 3
Ларенков, А. А., Mitrofanov, Y. A., & Rakhimov, M. G. (2022) · The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products Regulatory Research and Medicine Evaluation · doi:10.30895/1991-2919-2022-12-4-455-467 · Cited by 2
Functional Imaging and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor
Kang, K. W. (2021) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2021.26.1.10 · Cited by 2
Lutetium-177: Production and Radiopharmaceuticals
Akit, A. A. (2023) · Nuclear Medicine Seminars · doi:10.4274/nts.galenos.2023.0006 · Cited by 2
“Bunlar arasında Lu-177 DOTATATE, “LUTATHERA” ticari adıyla yetişkinlerde somatostatin reseptörü pozitif tümörlerin tedavisi için Avrupa ve ABD’de ruhsatlanmıştır (39,40).”
Alpha Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors
Beydağı, G., Selçuk, N. A., & Kabasakal, L. (2023) · Nuclear Medicine Seminars · doi:10.4274/nts.galenos.2023.0015 · Cited by 1
Hoerres, R., Kamboj, R., Pryor, N., et al. (2024) · ACS Omega · doi:10.1021/acsomega.4c05699 · Cited by 1
Hematological Side Effects of 177Lu-DOTA-TATE Therapy in Patients with NENs
Carideo, L., Meucci, R., Campagna, G., Russo, V., D’Ippolito, E., Rinzivillo, M., Panzuto, F., & Prosperi, D. (2024) · Hemato · doi:10.3390/hemato6010001 · Cited by 1
Clinical Evidence of Combining Radiopharmaceutical Therapy With Immune Checkpoint Inhibitors
Idrissou, M. B., Muralidhar, A., Hernandez, R. T., & Sodji, Q. H. (2025) · Applied Radiation Oncology · doi:10.37549/aro-d-24-00039 · Cited by 2
Durma, A. D., Saracyn, M., Jóźwik−Plebanek, K., Brodowska-Kania, D. A., Kołodziej, M., Żmudzki, W., & Kamiński, G. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07418-5 · Cited by 2
Wu, X., Liao, J., Chen, W., & Dou, J. (2025) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000002015 · Cited by 1
Cass, A. S., Skotte, E. A., Wheless, M. C., et al. (2025) · Cancers · doi:10.3390/cancers17213472 · Cited by 1
Velo, A. F., Carter, L. M., & Humm, J. L. (2025) · EJNMMI Physics · doi:10.1186/s40658-025-00810-y · Cited by 4
“177 Lu is the radionuclide in the two approved tumor targeting theranostic agents, Luta-thera™ [1] and Pluvicto™ [2], used to treat neuroendocrine and prostate cancers, respectively.”
Baranova, O. D., Krylov, A. S., Zhulikov, Y. A., et al. (2026) · Journal of oncology diagnostic radiology and radiotherapy · doi:10.37174/2587-7593-2025-8-4-22-29 · Cited by 1
Zhu, Y., Zhong, G., Zhang, W., Wei, W., Yin, B., & Zhang, K. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02700-x · Cited by 4
Wang, J., Pang, X., Lian, J., & Lu, H. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1758639 · Cited by 1
Gómez-Sánchez, M., Blanco‐González, E., Montes-Bayón, M., et al. (2026) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-026-00442-2 · Cited by 1
Decoding GPCR signaling reprogramming in cancer: molecular mechanisms and therapeutic implications
Aldeyarbi, S. M., El-Deyarbi, M., Hussein, A. A., Adi, Z. S., & Aburuz, S. (2026) · Molecular Medicine · doi:10.1186/s10020-026-01491-8 · Cited by 2
“…transfer being high, which causes double-strand DNA breaks and rapid cell death; In addition, alpha particles have a range of about 2–3 cell diameters (50–100 µm), which is short, causing less surrounding damage to healthy cells (Nock et al. 2023; Hennrich and Kopka 2019b; Eychenne et al. 2020).”
Yamamoto, T., Nakashima, K., Kazuta, N., et al. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00272 · Cited by 1
Synthetic Approaches to the New Drugs Approved During 2024
France, S. P., Lindsey, E. A., McInturff, E. L., Berritt, S., Flick, A. C., Fink, S. J., Gibson, T., Gray, K. C., Hubbell, A. K., Johnson, A. M., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00287 · Cited by 2
Alum, E. U., Obasi, D. C., Uzor, S., Eji, M. O., Amadi, E. B., Emeruwa, A. P., Akwari, A. A., Okoroh, P. N., Aniokete, U. C., & Alum, B. N. (2026) · Nanomedicine · doi:10.1080/17435889.2026.2705388 · Cited by 6
Are Radiopharmaceutical Therapy Trials Designed to Undertreat?
Bertolet, A. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00796 · Cited by 1
Antibody–Drug Conjugates and Peptide–Drug Conjugates: Current Understandings and Future Perspectives
Zheng, R., Li, S., Zhang, Z., Niu, M., Fei, J., Zhang, J., Zhou, J., Wu, K., Yi, M., & Li, T. (2026) · MedComm · doi:10.1002/mco2.70897 · Cited by 1
“Lutathera (177Lu-Dotatate) is the world’s first approved PDC and also the first FDA-approved peptide receptor-radionuclide therapy [ 264 ].”
Myers, A., & Chitwood, H. (2020) · Clinical journal of oncology nursing · doi:10.1188/20.cjon.129-133 · Cited by 2
Ni, Y., Ye, Q., Liu, X., et al. (2023) · Health Physics · doi:10.1097/hp.0000000000001700 · Cited by 1
Enhancement of bioavailability of therapeutics using drug conjugation approach: an in-depth review
Nishad, S., Mazumder, R., Padhi, S., Malakapogu, R. B., & Pandey, P. (2023) · International Journal of Polymeric Materials · doi:10.1080/00914037.2023.2243368 · Cited by 1
Recent advances in functionalized macrocyclic polyamines for medicine applications
Chang, H., Qiao, R., & Li, C. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.110675 · Cited by 2
Khomenko, I. A., Kormazeva, E. S., Богомолова, Т. В., et al. (2024) · The European Physical Journal Plus · doi:10.1140/epjp/s13360-024-05917-2 · Cited by 1
Ballal, S., Sheokand, P., Yadav, M. P., Roesch, F., Viswanathan, R., Satapathy, S., Tripathi, M., Moon, E. S., Mishra, P., Rastogi, S., et al. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000005649 · Cited by 1
Selecting Peptides for Targeted Delivery of Drugs Inside Cancer Cells
Kalishwaralal, K., Abhishek, A., Sharma, S., & Firer, M. A. (2025) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-025-10712-3 · Cited by 2
Franco, M. D., Durmo, R., Paolo, M. L. D., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1590478 · Cited by 1
Radiological Technology for Targeted Radionuclide Therapy
Hanaoka, K., Miyaji, N., Yoneyama, H., Ogawa, M., Maeda, T., Sakaguchi, K., Iimori, T., & Tsushima, H. (2020) · Japanese Journal of Radiological Technology · doi:10.6009/jjrt.2020_jsrt_76.12.1237 · Cited by 1
Tipnis, S. V., Rieter, W. J., Henderson-Suite, V., & Gordon, L. L. (2021) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.121.262820 · Cited by 2
Diusenova, S., Arkhipov, S. G., Авдеев, Д. В., et al. (2021) · Crystals · doi:10.3390/cryst12010012 · Cited by 1
Repurposed Effect of 177Lu-DOTATATE in the Treatment of Mantle Cell Lymphoma
Elajami, M. K., Burton, L. P., Bahmad, H. F., Chaaya, G., & Schwartz, M. (2022) · Current Oncology · doi:10.3390/curroncol29100594 · Cited by 3
Concepts and Issues for Therapeutic Radiopharmaceuticals
Sowa, A. R., & Scott, P. J. H. (2020) · doi:10.1002/9781119500575.ch2 · Cited by 1
Supramolecular inorganic chemistry: from form to function
Buccella, D., Sánchez, R. H., Morrow, J. R., Pierre, V. C., & Wilson, J. J. (2025) · Supramolecular chemistry · doi:10.1080/10610278.2025.2510449 · Cited by 1
“This fact is evidenced by the two recent FDA approvals of 177 Lu-based drugs Lutathera® and Pluvicto™ [28,29].”
Sadiq, S., Naveed, A. K., Waheed, P., Qaiser, F., & Hashmi, S. N. (2018) · The Professional Medical Journal · doi:10.29309/tpmj/18.4477
Middle Molecular and Conjugation Strategies for Development of Bioactive Middle Molecules
Manabe, Y., Shimoyama, A., Kabayama, K., & Fukase, K. (2020) · Journal of Synthetic Organic Chemistry Japan · doi:10.5059/yukigoseikyokaishi.78.527
Conjugation Strategies for Development of Bioactive Middle Molecules
Manabe, Y., Shimoyama, A., Kabayama, K., & Fukase, K. (2021) · Springer eBooks · doi:10.1007/978-981-16-2458-2_1
Quantitative Imaging of Breast Cancer: Screening, Staging, and Monitoring
Jones, E. F., Hathi, D., & Hylton, N. M. (2021) · doi:10.1063/9780735423558_006
Kim, H., Lee, H. Y., Lee, S., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14297
HEDEFE YÖNELİK TEDAVİDE GÜNCEL YAKLAŞIMLAR: LUTESYUM-177 İLE İŞARETLİ RADYOFARMASÖTİKLER
HIŞIR, D., Ekinci, M., & İlem‐Özdemir, D. (2022) · Ankara Universitesi Eczacilik Fakultesi Dergisi · doi:10.33483/jfpau.1007773 · Cited by 1
Aloj, L. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198818502.003.0019
Mitra, A., Lad, S., Sahu, S., et al. (2022) · PubMed · doi:10.22038/aojnmb.2021.59607.1416
“2022; 10(2):109-116 115 of [177Lu]LuCl3 indicates [177Lu]Lu3+ does not exist in free ionic species and rather there exists an ionic bond between [177Lu]Lu3+ and Cl-, since the [177Lu]Lu3+ is in 0.”
BackgroundInfluentialInterventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!
Elhelf, I. A. S., & Clemenshaw, M. N. (2022) · Seminars in Interventional Radiology · doi:10.1055/s-0042-1759703
Nanoparticles for Enhanced Radiotherapy and Imaging Applications
Tng, D. J. H., Chong, L. M., Chua, M. L. K., Zhang, Y., & Yong, K. (2022) · Springer eBooks · doi:10.1007/978-3-031-09636-5_2
Receptor-Specific Radionuclide Therapy
Lepareur, N., & Bourgeois, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_303-1
Theranostics in Neuroendocrine Tumors
Vallabhajosula, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-23205-3_21
DeSai, C., Knipe, H., & Glick, Y. (2023) · Radiopaedia.org · doi:10.53347/rid-171565
Pavlenko, E. P., Ларенков, А. А., & Mitrofanov, Y. A. (2023) · Drug development & registration · doi:10.33380/2305-2066-2023-12-4-1525
Case Study #4: Lutathera, a Gold Standard for Peptide Receptor Radiopharmaceutical Therapy
Stasio, G. D. D., Farulla, L. S. A., Botta, F., Gilardi, L., & Grana, C. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-39005-0_14
Bdair, H., Kang, M. S., Ottoy, J., et al. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3499-8_16
Radioembolisation mit Harz- und Glas-Mikrosphären
Ilhan, H., Stegger, L., & Ahmadzadehfar, H. (2023) · Angewandte Nuklearmedizin · doi:10.1055/a-2168-2063
“Insbesondere nach Zulassung der Peptid-Rezeptor-Radionuklid-The-rapie mit Lutetium-177-markierten Somatostatin-Ana-loga für metastasierte gastroenteropankreatische NET [63] kann die Wahl der geeigneten Radionuklidtherapie auf individueller Ebene komplex sein.”
BackgroundTatsi, A., Μάινα, Θ., Waser, B., Krenning, E. P., de Jong, M., Reubi, J. C., Cordopatis, P. A., & Nock, B. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031921
Mitrofanov, Y. A., Bubenshchikov, V. B., Belousov, A. V., et al. (2023) · High Energy Chemistry · doi:10.31857/s0023119323010096
Radioembolisation mit Harz- und Glas-Mikrosphären
Ilhan, H., Stegger, L., & Ahmadzadehfar, H. (2024) · Radiopraxis · doi:10.1055/a-2289-6899
Kupitz, D., Einspänner, E., Wissel, H., et al. (2024) · Medical Physics · doi:10.1002/mp.17272
Bibika, M., Kanellopoulos, P., Rouchota, M. G., Loudos, G. K., Nock, B. A., Krenning, E. P., & Μάινα, Θ. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091223 · Cited by 2
Interim PET/CT with [68Ga]Ga-DOTA-peptides in NET prognostication: is Δ-radiomics the next frontier?
Filippi, L., & Schillaci, O. (2024) · European Radiology · doi:10.1007/s00330-024-11117-4
Management of Recurrent Skull Base Meningiomas
Govind, S., Nandoliya, K. R., Khazanchi, R., Jain, R., Sita, T. L., Kumthekar, P., & Magill, S. T. (2024) · Springer eBooks · doi:10.1007/978-3-031-76680-0_21 · Cited by 1
Telomere, DNA Damage Response, and Nanomedicine: A Triad for Cancer Treatment Innovation
Afshar, Y., Sharif, H., & Rezaei, N. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_486
Metastatic Insulinoma Managed With Continuous Glucose Monitoring in a Young Female Patient
Bondarenko, D., Thelmo, F., & Shirodkar, M. K. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf005 · Cited by 2
Towards the Stable Chelation of Radioantimony(V) for Targeted Auger Theranostics
Olson, A. P., Schrage, B. R., Islam, M. F., Fletcher, L. S., Verich, F., Dierolf, M. A., Aluicio‐Sarduy, E., Becker, K. V., Driscoll, D. M., Girish, N., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202423878
Peptide receptor radionuclide therapy ( PRRT ) special issue
Navalkissoor, S., & Millar, R. P. (2025) · Journal of Neuroendocrinology · doi:10.1111/jne.70014
Advances with radiopharmaceutical therapy in cancer
Lepareur, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00002-9
Koniar, H., & Schaffer, P. C. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677139-00056
Identifying New Molecular Modalities for Radionuclide Therapy Using Macrocyclic Peptide Mimetics
Charych, D. H., & Harding, T. A. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677139-00217
Targeted Radiopharmaceuticals: Clinical Development and Commercial Landscape
Agarwal, E., & Srivastava, V. (2025) · Royal Society of Chemistry eBooks · doi:10.1039/9781837677139-00001
Dose-Dependent Cellular Phenotypic Change Induced by 177Lu-Oxodotreotide Treatment in IMR-32 Cells
Xue, S., Zheng, X., Pu, B., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13071543
Peikin, J. M., Tara, V. K., Johnson, T. R., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5372636
New modalities: Drugging the undruggable GPCR targets
Zawadzki, P., Graczyk, P. P., & Staroń, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00030-3
Zhang, Y., Yan, C., Yu, S., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01019
Receptor-Specific Radionuclide Therapy
Lepareur, N., & Bourgeois, M. (2025) · Springer eBooks · doi:10.1007/978-3-032-00773-5_303
Gerdan, G., Yüksel, Ş., & Akyerli, C. B. (2025) · SDÜ Tıp Fakültesi Dergisi · doi:10.17343/sdutfd.1562838
Burkitbayev, Z. (2025) · Oncology Nuclear Medicine and Transplantology · doi:10.63946/onmt/17161
“The rise in cancer incidence, the promise of personalized therapy, the revolution in radiopharmaceuticals for both diagnostics and treatment (theranostics) [8, 9], and the remarkable innovations in transplant immunology are defining the future of patient care [10].”
Lewis, M. A., Thomas, J. S., & Yen, L. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00474
Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!
Elhelf, I. A. S., & Clemenshaw, M. N. (2025) · Nuklearmedizin - NuclearMedicine · doi:10.1055/a-2729-8686
“Complete blood cell counts renal and liver functions are monitored in between treatment sessions to determine eligibility to receive next cycles [4].”
Yazdi, S. I., Yazdani, E., Arabi, H., et al. (2025) · Current Radiopharmaceuticals · doi:10.1016/j.craph.2025.100010
Maskur, Pertiwi, L. D., Sugiharto, Y., et al. (2026) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-025-10698-8
“To date, two 177 Lu-based radiopharma-ceuticals have been approved for commercial distribution, namely, [ 177 Lu]Lu-DOTATATE (Lutathera®) and [ 177 Lu] Lu-PSMA-617 (Pluvicto®) for the treatment of gastroenter-opancreatic neuroendocrine and prostate cancer, respectively [7–9].”
Voss, S., Sagar, A., Tiberghien, A. C., Hughes, R. J. L., Chen, L., Rioja, I., Frigerio, M., Skynner, M. J., & Spring, D. R. (2026) · Journal of Peptide Science · doi:10.1002/psc.70071
“Radiopharmaceuticals that gained approval in the last decade include Lutathera (EMA 2017, FDA 2018) [91] and Pluvicto (EMA and FDA 2022) [92] which both utilise peptidic ligands to bind to their cognate receptors within tumours.”
Desarrollo de radiofármacos para la teragnosis de tumores neuroendocrinos
Torres, F. D., Iruela, J. A. P., & Bautista‐Aguilera, Ó. M. (2026) · FarmaCiencia Revista de Divulgación Científica · doi:10.37536/fc.3341 · Cited by 1
Ladrière, T., Chrétien, B., Bignon, A.-L., Bouhier‐Leporrier, K., Dolladille, C., & Vigne, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-36823-5 · Cited by 2
Klomp, M. J., Erkens‐Schulze, S., van den Brink, L., van Weerden, W. M., & Dalm, S. U. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01393-0
Synthèse et évaluation de traceurs peptidiques hétérobivalents pour l’imagerie moléculaire
Bailly, T. (2022) · theses.fr (ABES) · doi:10.70675/ff7dcc7dzaeecz4574z851bzb468baa1e15b
⁵²Mn and ¹⁶⁵Er production for bimodal imaging and therapy applications
Silva, I. D. (2024) · theses.fr (ABES) · doi:10.70675/914f7bdfz98c2z472bz97f9z5825e991ef52
Radionuclide theranostics: advances and clinical applications in lung cancer
Yang, Y., Fu, J., Tang, S., Liu, T., Hu, H., Guo, H., Wen, L., Yang, Y., Liu, C., Zhang, Y., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1782938 · Cited by 1
Zhao, R., Deng, Y., Jin, W., et al. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c01617
Schoorens, K., Santa, L., & Mattina, A. J. D. (2025) · Clinical Insights in Eyecare · doi:10.66574/001c.140872
Dong, Z., Yan, S., Liu, X. J., & Gu, P. (2026) · Med Research · doi:10.1002/mdr2.70068
Qu, D., Shao, C., Ji, X., Huang, Y., Chen, T., Li, J., Zhou, H., Shi, Y., Wang, H., Liu, J. Y., et al. (2026) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1177/10849785261448523
Metadata
- Authors
- Hennrich, U., & Kopka, K.
- Affiliations
- German Cancer Research Center (DE)
- Corresponding author
- Hennrich, Ute
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2019-07-29
- Volume
- 12
- Issue
- 3
- Pages
- 114
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC6789871
- OpenAlex
- W2965362447
- Semantic Scholar
- 541d92ea7d4ff1ddec5cefec2755259d1aa26d0e
- Cited by
- 440
- References
- 26
- Citations by year
- 2026: 58 · 2025: 87 · 2024: 88 · 2023: 61 · 2022: 58 · 2021: 46 · 2020: 38 · 2019: 3
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- 177Lu-DOTATATE, lutetium-177, peptide receptor radionuclide therapy, somatostatin receptors, DOTATATE, gastroenteropancreatic neuroendocrine tumors, radiopharmaceuticals, targeted radionuclide therapy, DNA double-strand breaks, cancer cell death
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Figure 1 Structure of [177Lu]Lu-DOTA-TATE (Lutathera®). Simplified writing of complexation [18].](https://figures.cochat.ai/paper-figures/b252f6f0df3d4eceb221f630640ad0bc/lutathera-the-first-fda-and-ema-approved-radiopharmaceutical-for-peptide-figure-1.jpg)
![Figure 2 Simplified overview on the mechanism of action of [177Lu]Lu-DOTA-TATE.](https://figures.cochat.ai/paper-figures/56d8de000b344458a3f6939340017c5b/lutathera-the-first-fda-and-ema-approved-radiopharmaceutical-for-peptide-figure-2.jpg)